NCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
Clinical Trials
34 trialsNCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00515372 2026-03-09
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03943173 2026-02-25
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03771651 2026-02-17
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
University of Oklahoma
Phase EARLY_PHASE1 Active not recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02884648 2026-02-06
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06483997 2026-01-29
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
Active not recruiting
NCT04095364 2026-01-14
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT04204811 2026-01-07
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05220033 2025-12-30
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
Phase NA Active not recruiting
NCT02726997 2025-12-18
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02068794 2025-11-18
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Mayo Clinic
Phase 1/2 Active not recruiting
NCT02659241 2025-10-14
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03355976 2025-10-09
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
Phase 2 Active not recruiting
NCT03029403 2025-09-19
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT06451263 2025-09-19
Nudge to Gynecologic Oncology
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT04387227 2025-09-18
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 2 Active not recruiting
NCT05406674 2025-07-20
CisCon
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT02122185 2025-06-08
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Active not recruiting
NCT02873962 2025-06-08
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06638931 2025-05-28
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT04575961 2025-05-23
PERCEPTION
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT06972693 2025-05-15
PERSONA-Ovary
European Institute of Oncology
Phase 4 Active not recruiting
NCT03017131 2025-03-28
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT01883297 2024-09-05
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
Phase 1 Active not recruiting
NCT04807166 2024-07-03
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT00799110 2024-06-11
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT03732950 2024-04-15
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting